Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-02
2007-10-02
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S114000
Reexamination Certificate
active
10845710
ABSTRACT:
This invention provides compounds of Formula (1a)–(1f), IIwherein:X, m, n, q, R1, R2, R3, R4, R5, R6, R7, R8, R9, Y, Q, Z, Z′, Z′″, Z″ and J are defined hereinbefore in the specification, which are useful in the treatment of cancer, stroke, myocardial infarction, neuropathic pain, osteoporosis, polycystic kidney disease, autoimmune disease, rheumatoid arthritis, and transplant rejection and process for producing said compounds.
REFERENCES:
patent: 6987116 (2006-01-01), Boschelli et al.
patent: 2002/0004511 (2002-01-01), Luzzio et al.
patent: 2007/0004675 (2007-01-01), Saavedra et al.
patent: 2007/0082880 (2007-04-01), Boschelli et al.
patent: 0 126 970 (1984-04-01), None
patent: WO 99/24440 (1999-05-01), None
patent: WO 00/56738 (2000-09-01), None
patent: WO 2000/66583 (2000-11-01), None
patent: 01/47892 (2001-07-01), None
patent: WO 01/47892 (2001-07-01), None
patent: WO 2001/72711 (2001-10-01), None
patent: WO 01/94353 (2001-12-01), None
patent: WO 03/013540 (2003-02-01), None
patent: 2006/030031 (2006-03-01), None
Avizienyte, Egle; et al., “Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signaling” Nature Cell Biology, Jul. 22, 2002, published online.
Blume-Jensen, Peter; et al., “Oncogenic Kinase signaling” Nature (May 17, 2001) vol. 411:355-365, Macmillan Magazines Ltd.
Boyce, Brendan F.; et al., “Requirement of pp60c-src Expression for Osteoclasts to Form Ruffled Borders and Resorb Bone in Mice”, The American Society for Clinical Investigation, Inc. Oct. 1992, 1622-1627, vol. 90 ISSN 0021-9738.
Bridges, Aj: et al., “Current progress towards the development of tyrosine kinase inhibitors as anticancer agents”, Emerging Drugs (1998) vol. 3:279-292, ISSN 1361-9195, Ashley Publications Ltd.
Campbell, Sharon L.; et al., “Increasing complexity of Ras signaling”, Oncogene (1998) vol. 17:1395-1413, ISSN 0950-9232/98, Stockton Press.
Davies, Donna E.; et al., “Targeting the Epidermal Growth Factor Receptor for Therapy of Carcinomas”, Biochemical Pharmacology, (1996) vol. 51:1101-1110, ISSN 0003-2952/96, Elsevier Science Inc.
Du, Jing; et al., Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD, The American Physiological Society (1995) C487-C495, ISSN 0363-6143/95.
Eliceiri, Brian P.; et al., “Selective Requirement for Src Kinases during VEGF-Induced Angiogenesis and Vascular Permeability”, Molecular Cell, (Dec. 1999) vol. 4:915-924, Cell Press.
Elliott, Richard L.; et al., “The Preparation of 2-(Heterocyclyl) Thieno[3,2-b] Pyridine Derivatives”, Tetrahedron (1987) vol. 43, No. 14:3295-3302, ISSN 0040-4020/87 Pergamon Journals Ltd., Great Britain.
Ellis, Lee M.; et al, “Down-regulation of Vascular Endothelial Growth Factor in Human Colon Carcinoma Cell Line Transfected with an Antisense Expression Vector Specific for c-src”, The Journal of Biological Chemistry, (1998) vol. 273 No. 2:1052-1057, The American Society for Biochemistry and Molecular Biology, Inc.
Folkman, Judah; et al., “Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease”, Nature Medicine (1995), vol. 1 No. 1:27-31.
Garrett, Michelle D.; et al., “CDK inhibition and cancer therapy”, Genetics & Development (1999) vol. 9:104-111, ISSN 0959-437X, Elsevier Science Ltd.
Gattone II, Vincent H.; et al., “Epidermal Growth Factor Ameliorates Autosomal Recessive Polycystic Kidney Disease in Mice”, Developmental Biology (1995) vol. 169:504-510, ISSN 0012-1606/95, Academic Press, Inc.
Glazer, Robert I.; et al., “The Protein Kinase ABCs of Signal Transduction as Targets for Drug Development”, Current Pharmaceutical Design, (1998) vol. 4:277-290, ISSN 1381-6182/98, Bentham Science Publishers B.V.
Gullick, W. J.; et al., “Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers”, British Medical Bulletin (1991) vol. 47 No. 1:87-98, The British Council.
Guo, Wei; et al., “Tyrosine Phosphorylation of the NR2B Subunit of the NMDA Receptor in the Spinal Cord during the Development and Maintenance of Inflammatory Hyperalgesia”, The Journal of Neuroscience, (Jul. 15, 2002) vol. 22 No. 14:6208-6217, ISSN 0270-6474/02/226208, Society for Neuroscience.
He, Zuwen; et al., “The Human Cytomegalovirus UL97 Protein is a Protein Kinase That Autophosphorylates on Serines and Threonines”, Journal of Virology, (Jan. 1997) vol. 71 No. 1:405-411, ISSN 0022-538X/97, American Society for Microbiology.
Kamens, Joanne S.; et al.; “Lck inhibitors as a therapeutic approach to autoimmune disease and transplant rejection”, Investigation Drugs (2001), vol. 2 No. 9:1213-1219, ISSN 1472-4472, PharmaPress Ltd.
Khan, Misbahul Ain; et al., “Thieno[2,3-b] pyridines and Thieno[3,2-b] pyridines by the Method of Gould-Jacobs”, J. Heterocyclic Chem., (Aug. 1977) vol. 14:807-812.
Loomis, William F.; et al., “Histidine Kinases in signal transduction pathways of eukaryotes”, Journal of Cell Science (1997) vol. 110:1141-1145, The Company of Biologists Ltd., Great Britain.
Mattsson, Erney; et al., “Current Concepts in Restenosis Following Balloon Angioplasty”, Trends in Cardiovascular Medicine, (1995) vol. 5 No. 5:200-204, ISSN 1050-1738/95, Elsevier Science Inc.
Modjtahedi, Helmout; et al., “The receptor for EGF and its ligands: Expression, prognostic value and target for therapy in cancer”, International Journal of Oncology, (1994) vol. 4:277-296.
Macias, Amparo; et al., “Prognostic Significance of the receptor for Epidermal Growth Factor in Human Mammary Carcinomas”, Anticancer Research (1987) vol. 7:459-464.
Nam, Jeong-seok; et al., “Src Family Kinase Inhibitor PP2 Restores the E-Cadherin/Catenin Cell Adhesion System in Human Cancer Cells and Reduces Cancer Metastasis”, Clinical Cancer Research, (Jul. 2002) vol. 8:2430-2436.
Missbach, M; et al., “A Novel Inhibitor of the Tyrosine Kinase Src Suppresses Phosphorylation of its Major Cellur Substrates and Reduces Bone Resorption In Vitro and in Rodent Models In Vivo” Bone (May 1999), vol. 24 No. 5:437-449, ISSN 2786-3282/99, Elsevier Science Inc.
Myers, Michael R.; et al., “Inhibitors of Tyrosine Kinases Involved in Inflammation and Autoimmune”, Current Pharmaceutical Design (1997), vol. 3:473-502, Bentham Science Publishers B.V.
Nauta, Jeroen; et al., “Biliary Epithelial Cells from Mice with Congenital Polycystic Kidney Disease are Hyperresponsive to Epidermal Growth Factor”, Pediatric Research (1995), vol. 37 No. 6:755-763, ISSN 0031-3998/95/3706-0755 International Pediatric Research Foundation, Inc., U.S.A.
Nister, Monica; et al., “Differential Expression of Platelet-derived Growth Factor Receptors in Human Malignant Glioma Cell Lines”, The Journal of Biological Chemistry, (Sep. 5, 1991) vol. 266 No. 25:16755-16763, The American Society for Biochemistry and Molecular Biology, Inc. U.S.A.
O'Reilly, Michael S.; et al., “Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth” Cell (Jan. 24, 1997), vol. 88:277-285, Cell Press.
O'Reilly, Michael S.; et al., “Angiostatin induces and sustains dormancy of human primary tumors in mice”, Nature Medicine (Jun. 1996), vol. 2 No. 6:689-692.
O'Reilly, Michael S.; et al., “Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma”, Cell (Oct. 21, 1994), vol. 79:315-328, Cell Press.
Paul, Robert; et al., “Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke”, Nature Medicine (Feb. 2001), vol. 7 No. 2:222-227, Nature Publishing Group.
Raines, Elaine W.; et al., “Multiple growth factors are associated with lesions of atherosclerosis: Specificity or redundancy”, BioEssays
Barrios Sosa Ana Carolina
Boschelli Diane Harris
Durutlic Haris
Wu Biqi
Zhang Nan
Chang Celia
Kirkpatrick & Lockhart Preston Gates & Ellis LLP
Wyeth
LandOfFree
Thieno[3,2-b]pyridine-6-carbonitriles and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thieno[3,2-b]pyridine-6-carbonitriles and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thieno[3,2-b]pyridine-6-carbonitriles and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3864797